WASHINGTON, May 16 (TNSFR) -- The U.S. Department of Health and Human Services National Institutes of Health National Center for Advancing Translational Sciences is considering the grant of an exclusive patent license to Neurala Bio Inc., a Delaware-based biotechnology company, for a series of inventions related to c-Abl tyrosine kinase inhibitory compounds. These inventions, protected by U.S. and Chilean patents as well as pending applications, encompass novel compounds designed to inhibit the . . .

Click here for more information about our products